Nelson Christopher M. 5
5 · QSAM Biosciences, Inc. · Filed Feb 14, 2022
Insider Transaction Report
Form 5
Nelson Christopher M.
DirectorCEO
Transactions
- Purchase
Preferred Series B Stock
2021-01-22$20000.00/sh+20$400,000→ 20 total - Other
Series E-1 Preferred Shares
2021-12-06−850→ 0 total - Award
Common Stock
2020-10-25+423,609→ 3,307,552 total - Award
Series E-1 Preferred Shares
2020-12-30+850→ 0 totalExercise: $0.00→ Common Stock (850,000 underlying) - Other
Common Stock
2021-12-06+2,883,943→ 2,883,943 total - Award
Options to buy common stock
2021-08-24+115,000→ 115,000 totalExercise: $0.36Exp: 2031-08-23→ Common Stock (115,000 underlying)
Footnotes (4)
- [F1]Pursuant to reclassification exempt tunde Rule 16b-7, each share of Series E-1 Preferred Stock was reclassified into and exchanged for shares of Common Stock of the Issuer under the terms of Exchange Agreement and Plan of Reorganization as filed with the SEC.
- [F2]Shares acquired upon conversion of deferred salary and earned bonus.
- [F3]The option vests semi-annually in two equal installments beginning on 02/24/2022.
- [F4]Series E-1 Preferred Stock was convertible at any time at the discretion of the holder at a ratio of 1000 shares of Common Stock per Series E-1 Preferred Stock.